TB-500 Calculator

Also known as: Thymosin Beta-4, Tβ4

Healing
Default: 5mg / 2.5mL / 0.5mgAdjust inputs to match your vial
About

What is TB-500?

TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-sequestering peptide produced in nearly all mammalian tissues. The TB-500 sequence corresponds to the active region of Tβ4 and is associated in preclinical research with cell migration, wound repair, and inflammation modulation. Veterinary use in equine sports medicine is well documented and the compound has been the subject of multiple regulatory enforcement actions by horseracing authorities. Human clinical evidence is limited to small Phase 1 and 2 trials in cardiac and dermatological indications. Common research protocols use a 2–5 mg loading phase given twice weekly for 4–6 weeks, followed by a 2 mg weekly maintenance phase. TB-500 is most often stacked with BPC-157 in research-peptide practice.

Common vial sizes
2 mglyophilized powder
5 mglyophilized powder
10 mglyophilized powder
Reference dose ranges
0.5 mg≈ 25 U-100 units (at 5mg / 2.5mL)
1 mg≈ 50 U-100 units (at 5mg / 2.5mL)
2 mg≈ 100 U-100 units (at 5mg / 2.5mL)
2.5 mg≈ 125 U-100 units (at 5mg / 2.5mL)
5 mg≈ 250 U-100 units (at 5mg / 2.5mL)
Reconstitution

How it's typically prepared

Reconstitute with bacteriostatic water and refrigerate at 2–8 °C; the peptide is generally stable for 4–8 weeks under refrigeration. Subcutaneous injection with a U-100 insulin syringe is the most common research route; intramuscular delivery is also reported in veterinary literature. Some research vendors supply TB-500 co-packed with BPC-157; verify which compound is in each vial before drawing.

FAQ

Frequently asked questions

What is the 'Wolverine stack'?
An informal name for combining BPC-157 with TB-500 for connective-tissue support. Both peptides are reconstituted separately and either drawn into a single syringe at the time of injection or alternated between sites.
Is TB-500 the same as Thymosin Beta-4?
TB-500 is an active fragment of Thymosin Beta-4 — closely related but not identical. Compounding pharmacies sometimes use the names interchangeably; check your specific product.
Is TB-500 FDA-approved?
No. TB-500 is not FDA-approved for any indication in humans. Full-length Thymosin Beta-4 has been investigated in Phase 2 trials for dry eye and post-MI cardiac repair under the development name TB-500 / RGN-352.
What is the typical TB-500 dose used in research literature?
Reported research protocols use 2–5 mg per dose during a 4–6 week loading phase, then 2 mg per week as maintenance. Subcutaneous administration with a U-100 insulin syringe is standard.
How is TB-500 different from BPC-157?
BPC-157 is a 15-amino-acid pentadecapeptide derived from human gastric juice protein. TB-500 is a synthetic fragment of Thymosin Beta-4. The two are mechanistically distinct but are commonly stacked because their reported tissue-repair effects are seen as complementary in research-peptide practice.
Why is TB-500 banned in horseracing?
Multiple racing jurisdictions — including the Hong Kong Jockey Club and FEI — list TB-500 as a prohibited substance because of its reported effects on cell migration and tissue repair, which are considered performance-enhancing in equine sport. Citations and disqualifications have been published since the early 2010s.
Compare

TB-500 head-to-heads

Notice

PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.